NO20063331L - Nikotinacetylcholinreseptorligander - Google Patents

Nikotinacetylcholinreseptorligander

Info

Publication number
NO20063331L
NO20063331L NO20063331A NO20063331A NO20063331L NO 20063331 L NO20063331 L NO 20063331L NO 20063331 A NO20063331 A NO 20063331A NO 20063331 A NO20063331 A NO 20063331A NO 20063331 L NO20063331 L NO 20063331L
Authority
NO
Norway
Prior art keywords
nikotinacetylcholinreseptorligander
ari
psychotic
prophylaxis
therapy
Prior art date
Application number
NO20063331A
Other languages
English (en)
Inventor
Glen Ernst
Robert Jacobs
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20063331L publication Critical patent/NO20063331L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Forbindelser av formel (I),. hvor D, Ari, E og Ar2 er som definert i beskrivelsen og de medfølgende krav, fremgangsmåter for deres fremstilling, farmasøytiske preparater som inneholder dem og deres anvendelse i terapi, spesielt i behandling eller profylakse av psykotiske eller intellektsvekkelsesforstyrrelser.
NO20063331A 2003-12-22 2006-07-18 Nikotinacetylcholinreseptorligander NO20063331L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53164803P 2003-12-22 2003-12-22
PCT/SE2004/001943 WO2005061495A1 (en) 2003-12-22 2004-12-20 Nicotinic acetylcholine receptor ligands

Publications (1)

Publication Number Publication Date
NO20063331L true NO20063331L (no) 2006-09-20

Family

ID=34710243

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063331A NO20063331L (no) 2003-12-22 2006-07-18 Nikotinacetylcholinreseptorligander

Country Status (14)

Country Link
US (1) US20070191422A1 (no)
EP (1) EP1699787A1 (no)
JP (1) JP2007515481A (no)
KR (1) KR20060123365A (no)
CN (1) CN1914200A (no)
AU (1) AU2004303740A1 (no)
BR (1) BRPI0417933A (no)
CA (1) CA2550847A1 (no)
IL (1) IL176073A0 (no)
MX (1) MXPA06007024A (no)
NO (1) NO20063331L (no)
SG (1) SG149051A1 (no)
WO (1) WO2005061495A1 (no)
ZA (1) ZA200605024B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
WO2006033446A1 (en) * 2004-09-21 2006-03-30 Astellas Pharma Inc. Aminoalcohol derivatives
WO2012007500A2 (de) 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
KR101928505B1 (ko) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
AU2001284646A1 (en) * 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282875A1 (en) * 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282910A1 (en) * 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
DE10156719A1 (de) * 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide

Also Published As

Publication number Publication date
IL176073A0 (en) 2006-10-05
EP1699787A1 (en) 2006-09-13
ZA200605024B (en) 2007-04-25
JP2007515481A (ja) 2007-06-14
SG149051A1 (en) 2009-01-29
CA2550847A1 (en) 2005-07-07
CN1914200A (zh) 2007-02-14
MXPA06007024A (es) 2006-08-31
US20070191422A1 (en) 2007-08-16
WO2005061495A1 (en) 2005-07-07
BRPI0417933A (pt) 2007-04-17
KR20060123365A (ko) 2006-12-01
AU2004303740A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
NO20062583L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20064584L (no) Tetrahydropyridoindolderivater
NO20074703L (no) Antibakterielle piperidinderivater
SE0301700D0 (sv) Novel compounds
NO20081844L (no) Terapeutiske forbindelser
NO20062335L (no) Nye diazaspiroalkaner og deres anvendelse i behandlingen av CCR8 medierte sykdommer
NO20050828L (no) lndol-3-svovelderivater
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20054329L (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
NO20083250L (no) Antibakterielle pyrrolopyridiner, pyrrolopyrimidiner og pyrroloazepiner
TW200738659A (en) Novel compounds
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
NO20070570L (no) Forbindelser.
NO20054361L (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
NO20062900L (no) Nye forbindelser
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application